(Johns Hopkins Medicine) In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug -- one with no known medical potential -- to a schedule IV drug such as prescription sleep aids, but with tighter control.
from EurekAlert! - Social and Behavioral Science https://ift.tt/2Q5D3dh
No comments:
Post a Comment